Acorda Therapeutics, Inc.: key financial figures for fiscal year 2023 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:
- Revenue (FY2023)
- $117.6M
- Net Income/Loss (FY2023)
- -$252.9M
- Total Assets (FY2023)
- $108.5M
- Total Equity (FY2023)
- $158.0M
- Cash Flows from Operating Activities (FY2023)
- -$14.0M
Source: Acorda Therapeutics, Inc. 10-K filing (FY2023). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
